Table 2 Ongoing Clinical Trials
Study | ClinicalTrials .gov Identifier | Sponsor | Tumor | Phase | Shh Drug inhibitor | Where it acts |
|---|---|---|---|---|---|---|
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery | NCT00275067 | Northwestern University Collaborators: Cephalon CTI BioPharma | Brain and Central Nervous System Tumors | Phase 1 Phase 2 | arsenic trioxide | Gli 1 inhibitor |
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas | NCT02523014 | Alliance for Clinical Trials in Oncology Collaborators: National Cancer Institute (NCI) GlaxoSmithKline Genentech, Inc. Brain Science Foundation | Intracranial Meningioma Recurrent Meningioma | Phase 2 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor |
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | NCT01878617 | St. Jude Children’s Research Hospital Collaborators: Genentech, Inc. National Cancer Institute (NCI) | Medulloblastoma | Phase 2 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor |
Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway | NCT01601184 | Centre Leon Berard Collaborator: Ministry of Health, France | Medulloblastoma | Phase 1 Phase 2 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor |
NCT Neuro Master Match - N2M2 (NOA-20) (N2M2) | NCT03158389 | University Hospital Heidelberg Collaborators: German Cancer Aid German Cancer Research Center National Center for Tumor Diseases, Heidelberg | Adult Glioblastoma | Phase 1 Phase 2 | GDC-0449 (vismodegib) (Erivedge) | Smo inhibitor |
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) (UVA-Gen001) | NCT02624388 | University of Virginia | Neuroblastoma, Rhabdomyosarcoma, Medulloblastoma, Brain Neoplasms | Phase 2 | Genistein | Gli 1 inhibitor |
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | NCT02770378 | University of Ulm Collaborators: Reliable Cancer Therapies Anticancer Fund, Belgium | Glioblastoma | Phase 1 | itraconazole | Smo inhibitor |